Physician profile
Patrick J Oconnell
NPI 1861503187
$789.13
in general payments reported to CMS, 2019-2025
14 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.37 · 2023: $67.40 · 2024: $505 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $425 · Consulting Fee: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $425.26 |
| Consulting Fee | $343.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $343.50 | 2024 | Combogesic IV |
| Glaxosmithkline, LLC. | $95.77 | 2023-2025 | Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $56.76 | 2023-2025 | Cologuard Collection Kit |
| Acadia Pharmaceuticals INC | $54.77 | 2025 | Nuplazid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.83 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $35.62 | 2025 | Jardiance |
| Hologic Sales and Service, LLC | $23.96 | 2025 | Aptima |
| Abbott Laboratories | $23.51 | 2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $20.37 | 2019 | |
| Astellas Pharma US INC | $19.85 | 2025 | Veozah |
| Medtronic, INC. | $18.08 | 2024 | Intellis Adaptivestim |
| Dexcom, INC. | $16.66 | 2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $14.73 | 2025 | |
| Phathom Pharmaceuticals, INC. | $13.72 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Oconnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.